Lantheus Medical Imaging of North Billerica, MA, is highlighting clinical data for a new PET radiopharmaceutical for imaging heart failure at this week's SNM meeting in Salt Lake City.
Researchers from Yale School of Medicine in New Haven, CT, presented preliminary phase I data showing that the agent, LMI 1195, can produce high-quality, well-defined images of the cardiac autonomic nervous system, which helps regulate the electrical activity of the heart and its ability to contract, according to Lantheus. The radiotracer also cleared quickly from the blood and had a favorable safety and dosimetry profile.
The study was an open-label, nonrandomized, single-dose trial designed to estimate the radiation dosimetry of LMI 1195 in healthy subjects undergoing a PET scan, to evaluate the safety and tolerability of the tracer, and to assess PET imaging parameters and image quality. Twelve healthy subjects received a single intravenous bolus injection of 150-250 MBq of LMI 1195. Mean effective dose was 0.026 ± 0.0012 mSv/MBq.
The data demonstrated that LMI 1195 yields a radiation dose comparable to that of other commonly used PET radiopharmaceuticals, and that good image quality is possible at the given dose. There were no adverse events associated with LMI 1195 in the study, Lantheus said.
Related Reading
Lantheus reports F-18 cardiac PET findings, June 7, 2010
Lantheus inks Ablavar contract with Amerinet, June 3, 2010
Lantheus receives Mo-99 from Europe, May 21, 2010
Lantheus touts SNM papers, May 19, 2010
Lantheus taps new VP, April 22, 2010
Copyright © 2010 AuntMinnie.com
